Sanofi, Regeneron Get Positive News from Drug Trials (SNY, REGN)
An anti-cholesterol drug being co-developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) has shown positive results in two Phase II trials the companies reported this morning. The investigational drug, SAR236553/REGN727, reduced levels of LDL-C, or “bad,” cholesterol…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
The drug could be important in helping patients reduce cholesterol levels further when they reach the limitations of what a statin drug can do, according to a press release.
The news has boosted Regeneron shares to a new 52-week high of $121.14, up more than 1%. Sanofy’s ADS are also up about 1% at $38.72.
Contact [email protected] for any questions or corrections.
Paul Ausick has been writing for 247Wallst.com for more than a decade. He has written extensively on investing in the energy, defense, and technology sectors. In a previous life, he wrote technical documentation and managed a marketing communications group in Silicon Valley.
He has a bachelor's degree in English from the University of Chicago and now lives in Montana, where he fishes for trout in the summer and stays inside during the winter.
